View the video from Galectin Therapeutics’ presentation at the Annual Meeting of Stockholders

Galectin Therapeutics (Nasdaq:GALT) hosted a corporate update webcast on Thursday, May 21, 2015, immediately following the business portion of the Company’s Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer discussed the company’s pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer. View the video replay below: